Tecnovula

Indications

• Female infertility due to anovulation
• Polycystic ovary syndrome (PCOS)
• Male hypogonadism
• Spermatogenesis stimulation

Dosage

Adults: Typically, clomiphene is administered at a dose of 50 mg daily for 5 days, starting on day 2 to

Mechanism of action

Clomiphene has both estrogenic and anti-estrogenic properties. It stimulates the hypothalamic-pituitary axis, leading to the release of gonadotropins such as FSH and LH. This promotes the development and maturation of ovarian follicles, ovulation, and the function of the corpus luteum, potentially resulting in pregnancy. Additionally, clomiphene competes with endogenous estrogens for binding to estrogen receptors, thus reducing the inhibitory effects of estrogens on gonadotropin release.

Pharmacodynamics

Clomiphene is categorized as a selective estrogen receptor modulator (SERM), which interacts with estrogen-receptor-containing tissues, including the hypothalamus and pituitary gland. Its administration leads to an increase in circulating gonadotropins, thereby initiating a cascade of endocrine events that culminate in ovulation. While clomiphene can enhance fertility by inducing multiple ovulations, it may also increase the risk of ovarian hyperstimulation syndrome and has been associated with potential weight gain and a slight increase in ovarian cancer risk.

Pharmacokinetics

Clomiphene is well-absorbed when taken orally and has a half-life that allows for its effects to persist over several days. The drug undergoes extensive hepatic metabolism, and its effects are mediated through its active metabolites. Clomiphene is eliminated through the urine, with both parent compound and metabolites detectable in urine. The pharmacokinetic profile facilitates its use in controlled ovulation induction.

Contra-indications

• Hypersensitivity to clomiphene or any of its components
• Pregnancy
• Undiagnosed abnormal vaginal bleeding
• Ovarian cysts or enlargement unrelated to polycystic ovary syndrome
• Liver disease
• Thyroid disease
• Adrenal gland disorder

Adverse effects

• Hot flashes
• Nausea
• Vomiting
• Abdominal discomfort
• Breast tenderness
• Ovarian hyperstimulation syndrome
• Visual disturbances
• Mood swings
• Increased risk of multiple pregnancies
• Weight gain
• Potential increased risk of ovarian cancer

Interactions

• May interact with other medications that affect estrogen levels
• Use with caution in patients taking anticoagulants due to potential interactions

Precautions

• Monitor for ovarian enlargement
• Assess for visual symptoms during treatment and after discontinuation
• Consider the risk of multiple pregnancies
• Evaluate liver function before initiating therapy
• Use caution in patients with a history of depression

Pregnancy

Clomiphene is contraindicated in pregnancy due to its effects on ovulation and potential risks to the fetus.

Breast-feeding

Clomiphene is not recommended during breastfeeding as it may affect milk production.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Tablets: 50 mg

Mechanism of action

Clomifene has both estrogenic and anti-estrogenic properties, but its precise mechanism of action has not been determined. Clomifene appears to stumulate the release of gonadotropins, follicle-stimulating hormone (FSH), and leuteinizing hormone (LH), which leads to the development and maturation of ovarian follicle, ovulation, and subsequent development and function of the coprus luteum, thus resulting in pregnancy. Gonadotropin release may result from direct stimulation of the hypothalamic-pituitary axis or from a decreased inhibitory influence of estrogens on the hypothalamic-pituitary axis by competing with the endogenous estrogens of the uterus, pituitary, or hypothalamus. Clomifene has no apparent progestational, androgenic, or antrandrogenic effects and does not appear to interfere with pituitary-adrenal or pituitary-thyroid function. CLOMIPHENE...AFFECTS SPERMIOGENESIS @ PRIMARY SPERMATOCYTE LEVEL. DOSE USED WAS 7.25 MG/DAY. EFFECT IS THOUGHT TO BE DUE TO ESTROGENICITY MEDIATED VIA HYPOTHALAMO-HYPOPHYSEAL AXIS... The antiestrogens tamoxifen and clomiphene are used primarily for the treatment of breast cancer and female infertility, respectively. These agents are used therapeutically for their antiestrogenic actions, but they can produce estrogenic as well as antiestrogenic effects. Both agents competitively block estradiol binding to its receptor, but the specific pharmacological activity they produce depends upon the species, the tissue, and the cellular endpoint measured. Consequently, these agents act as antagonists, agonists, or partial agonists depending upon the context in which they are used. Clomiphene and tamoxifen clearly bind to the estrogen receptor and can prevent the binding of estrogens. However, there are indications that the drugs and estradiol may interact with overlapping but slightly different regions of the ligand binding site of the estrogen receptor. Depending upon the specific cellular context and gene in question, antiestrogen binding may yield a receptor complex that has full, partial, or no intrinsic activity. Clomiphene may stimulate ovulation in women with an intact hypothalamic-pituitary-ovarian axis and adequate endogenous estrogens who have failed to ovulate. In these cases, it is thought that the drug opposes the negative feedback of endogenous estrogens resulting in increased gonadotropin secretion and ovulation. Most studies indicate that clomiphene increases the amplitude of LH and FSH pulses, without a change in pulse frequency. This suggests the drug is acting largely at the pituitary level to block inhibitory actions of estrogen on gonadotropin release from the gland and/or is somehow causing the hypothalamus to release larger amounts of gonadotropin-releasing hormone per pulse. Initial animal studies with clomiphene showed slight estrogenic activity and moderate antiestrogenic activity, but the most striking effect was the inhibition of the pituitary's gonadotropic function. In both male and female animals, the compound acted as a contraceptive.

Pharmacodynamics

Clomifene (previously clomiphene) is an orally administered, non steroidal, ovulatory stimulant that acts as a selective estrogen receptor modulator (SERM). Clomifene can lead to multiple ovulation, and hence increase the risk of conceiving twins. In comparison to purified FSH, the rate of ovarian hyperstimulation syndrome is low. There may be an increased risk of ovarian cancer and weight gain. Clomifene is capable of interacting with estrogen-receptor-containing tissues, including the hypothalamus, pituitary, ovary, endometrium, vagina, and cervix. It may compete with estrogen for estrogen-receptor-binding sites and may delay replenishment of intracellular estrogen receptors. Clomifene initiates a series of endocrine events culminating in a preovulatory gonadotropin surge and subsequent follicular rupture. The first endocrine event, in response to a course of clomifene therapy, is an increase in the release of pituitary gonadotropins. This initiates steroidogenesis and folliculogenesis resulting in growth of the ovarian follicle and an increase in the circulating level of estradiol. Following ovulation, plasma progesterone and estradiol rise and fall as they would in a normal ovulatory cycle.